DS-2248

DS-2248 is an orally bioavailable small molecule inhibitor of Heat Shock Protein 90 (Hsp90) developed by Daiichi Sankyo. Hsp90 is a molecular chaperone that plays a critical role in the folding, stabilization, and activation of numerous 'client' proteins, many of which are oncogenic drivers such as mutated EGFR, ALK, and HER2. By binding to Hsp90, DS-2248 disrupts the chaperone's ability to stabilize these client proteins, leading to their degradation via the ubiquitin-proteasome pathway. This mechanism results in the simultaneous inhibition of multiple signaling pathways essential for tumor cell survival and proliferation. DS-2248 was investigated in Phase 1 clinical trials for the treatment of advanced solid tumors, with a specific focus on non-small cell lung cancer (NSCLC) patients who had developed resistance to EGFR or ALK tyrosine kinase inhibitors. However, the clinical development of the compound was terminated.